Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Encouraging People To Sit Less And Eat Better Through Workplace E-Mail Intervention Program
An e-mail intervention program is an effective way to significantly improve diet and physical activity by helping people move more, sit less, and make healthier food choices, according to a Kaiser Permanente Division of Research study in the American Journal of Preventive Medicine.

Health And Safety Executive Warns Of Dangers In Failing To Maintain Plant Equipment After Driver's Death, UK
The Health and Safety Executive has warned of the danger of not maintaining plant equipment after the death of a telescopic forklift truck driver, who was crushed between the descending arm and side of his vehicle.
News of the day
Direct Flow Medical Announces Fifth Patent Issuance Of Their Unique Percutaneous Aortic Valve Technology
Direct Flow Medical, Inc. a privately held, emerging medical device Company developing a next generation, minimally invasive implant to treat patients with heart valve disease announced the issuance of its 5th patent on their Percutaneous Aortic Valve (PAV) Technology. The patent (USP# 7,534,259) entitled: "Nonstented Heart Valves with Formed in situ Support" provides further protection for this second generation PAV device.
Mental Health

Enzon Commences Phase II Trial Of PEG-SN38

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer. "We are pleased to have the first PEG-SN38 Phase II trial open in early summer as promised," said Jeffrey H. Buchalter, Enzon"s chairman and chief executive officer. "We are encouraged by the safety profile in the Phase I trials and are looking forward to this next phase of development." Two Phase I studies were conducted evaluating different dosing schedules of PEG-SN38. The dose limiting toxicity was febrile neutropenia. No cumulative toxicity was reported. A recommended Phase II dose was established in April 2009. "We are very excited to have played a key role in the Phase I testing of this novel cancer compound and are very interested to see its continued development," stated Dr. Anthony Tolcher, a leading principal investigator in the Phase I trials from START (South Texas Accelerated Research Therapeutics) in San Antonio, Texas. On Tuesday, June 23, 2009 at 2:00 p.m. ET, Enzon will host a conference call with two of its clinical investigators to discuss PEG-SN38. Dr. Anthony Tolcher, who has experience in the Phase I trials, will participate on the call. Additionally, Dr. Richard Goldberg of The University of North Carolina at Chapel Hill, the lead principal investigator in the Phase II trial, will be available to provide their perspective and answer questions on PEG-SN38. About PEG-SN38 SN38 is the active metabolite of the widely used cancer drug irinotecan (also CPT-11), marketed as Camptosar® in the U.S. Although unmodified SN38 is 1,000 times more potent than CPT-11, it has not been converted into a viable drug candidate because of its insolubility. Using Enzon"s proprietary PEGylation technology, the Company developed PEG-SN38 (EZN-2208), which results in a compound with excellent pharmaceutical properties as shown in animal models: increased solubility, higher exposure, and longer half-life than unmodified SN38. Enzon Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009